{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:38:17Z","timestamp":1770968297569,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1016\/s0149-2918(02)85148-7","type":"journal-article","created":{"date-parts":[[2002,10,10]],"date-time":"2002-10-10T23:00:46Z","timestamp":1034290846000},"page":"736-751","source":"Crossref","is-referenced-by-count":38,"title":["A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia"],"prefix":"10.1016","volume":"24","author":[{"given":"Mark H.","family":"Gotfried","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Dattani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernie","family":"Riffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen J.","family":"Devcich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Busman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard F.","family":"Notario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0149-2918(02)85148-7_BIB1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12019-000-0031-8","article-title":"An update on community-acquired pneumonia in adults","volume":"26","author":"Gotfried","year":"2000","journal-title":"Compr Ther"},{"issue":"23 Suppl","key":"10.1016\/S0149-2918(02)85148-7_BIB2","first-page":"S1216","article-title":"Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure","volume":"6","author":"Spiritus","year":"2000","journal-title":"Am J Managed Care"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1164\/ajrccm.160.2.9808045","article-title":"Etiology of community-acquired pneumonia: Impact of age, comorbidity, and severity","volume":"160","author":"Ruiz","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/75.11.1161","article-title":"Antimicrobial resistance in Streptococcus pneumoniae: Implications for patients with community-acquired pneumonia","volume":"75","author":"Chenoweth","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 2","key":"10.1016\/S0149-2918(02)85148-7_BIB5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/314058","article-title":"Importance of atypical pathogens of community-acquired pneumonia","volume":"31","author":"Plouffe","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB6","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s100960050419","article-title":"Prospective study of community-acquired pneumonia of bacterial etiology in adults","volume":"18","author":"Sopena","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB11","first-page":"329","article-title":"Empirical therapy of community-acquired pneumonia: Macrolides are not ideal choices","volume":"12","author":"Bartlett","year":"1997","journal-title":"Semin Respir Infect"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.43.5.1310","article-title":"Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong","volume":"43","author":"Ho","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00003495-199958040-00010","article-title":"Gatifloxacin","volume":"58","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB15","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infect Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.116.4.974","article-title":"A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia","volume":"116","author":"Moola","year":"1999","journal-title":"Chest"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)88271-5","article-title":"Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia","volume":"21","author":"Ramirez","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB18","year":"1998"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB19","year":"1998"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB21","first-page":"S71","article-title":"Community acquired pneumonia in an outpatient population: Safety and efficacy of once-daily clarithromycin ER vs. levofloxacin","volume":"17","author":"Olson","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0149-2918(01)80060-6","article-title":"Pharmacokinetics and tolerability of extended-release clarithromycin","volume":"23","author":"Guay","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/S0149-2918(02)85148-7_BIB23","unstructured":"Biaxin\u00ae [package insert]. East Hanover, NJ: Sandoz Pharmaceuticals Corp; 1993."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291802851487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291802851487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:34:24Z","timestamp":1583415264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291802851487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0149291802851487"],"URL":"https:\/\/doi.org\/10.1016\/s0149-2918(02)85148-7","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}